RTTNews | Oct 22, 2020 10:15AM EDT

10:14 Thursday, October 22, 2020 (RTTNews.com) - Shares of Bio-Path Holdings, Inc. (BPTH) are gaining more than 22 percent or $0.93 in Thursday's morning trade at $5.04.

Thursday, Bio-Path said that the United States Patent and Trademark Office has issued a notice of allowance for a strategic patent for the company's lead product candidate, Prexigebersen, in combination with either a cytidine analog such as Decitabine or Bcr-Abl tyrosine kinase inhibitors Dasatinib and Nilotinib in a variety of cancers.

Prexigebersen in combination with Decitabine is currently in a Phase 2 clinical trial as a treatment for acute myeloid leukemia.

Bio-Path has traded in a range of $2.92 to $12.54 in the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3138529/stock-alert-bio-path-jumps-22-on-new-patent-for-prexigebersen.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved